Compare Cintas Corporation (CTAS) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Ginkgo Bioworks Holdings Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $79.86B), while Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M). The key difference: Cintas Corporation is far larger — about 104.6× Ginkgo Bioworks Holdings Inc's market cap, and Cintas Corporation pays a 1.03% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| CTAS | DNA | |
|---|---|---|
Market Cap | $79.86B | $763.64M |
Volume | 1,323,583 | 3,204,177 |
Sector | Industrials | Health |
52-Week High | $216.53 | $15.83 |
52-Week Low | $163.55 | $5.48 |
Typical Hold Time | 124 Days | 7 Days |
Enterprise Value | $82.33B | $865.59M |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2027 results with revenue of $3.01 billion, beating estimates, and raised full-year guidance. Fundamentals show robust revenue growth, expanding margins, and high profitability, though valuation multiples like a P/E of 39.67 are elevated. Analyst sentiment is moderately bullish with a consensus price target of $234.60.
The outlook for CTAS is positive, driven by durable growth, record margins, and strong capital returns. Key opportunities include consistent earnings beats and market leadership, while risks involve high valuation sensitivity and competitive pressures. The stock's upside potential is supported by analyst targets, but investors should monitor execution against guidance.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
